Immunotherapy for IgM anti-Myelin-Associated Glycoprotein paraprotein-associated peripheral neuropathies

Lunn, MPT; Nobile‐Orazio, Eduardo

doi:10.1002/14651858.cd002827

Cited by 96 publications

(136 citation statements)

References 51 publications

Supporting

Mentioning

131

Contrasting

Unclassified

Order By: Relevance

“…IgM-PNP may lead to significant disability 1. Despite the presence of auto-antibodies, treatment strategies that target toxic B cell clones have been largely unsuccessful in patients with IgM-PNP 2. However, results from two recent randomised placebo-controlled clinical trials suggest that rituximab treatment may lead to improvement in function in a subgroup of patients 3 4.…”

Section: Introductionmentioning

confidence: 99%

Fc receptor IIIA genotype is associated with rituximab response in antimyelin-associated glycoprotein neuropathy

Stork

Notermans

Berg

et al. 2014

Journal of Neurology, Neurosurgery & Psychiatry

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

Fc receptor IIIA genotype is associated with rituximab response in antimyelin-associated glycoprotein neuropathy

Stork

Notermans

Berg

et al. 2014

Journal of Neurology, Neurosurgery & Psychiatry

View full text Add to dashboard Cite

show abstract

“…IVIG has been shown to be of benefit in IgM paraproteinaemic neuropathies in RCT at up to 4 weeks 111. Cyclophosphamide and prednisolone in combination may be effective in the longer term, but the toxic side effects limit its applicability in what is usually a relatively slowly progressive disease 112 113.…”

Section: Paraproteinaemic Neuropathymentioning

confidence: 99%

Diagnosis and treatment in inflammatory neuropathies

Lunn

Willison

2009

Postgraduate Medical Journal

View full text Add to dashboard Cite

The inflammatory neuropathies are a large diverse group of immune-mediated neuropathies that are amenable to treatment and may be reversible. Their accurate diagnosis is essential for informing the patient of the likely course and prognosis of the disease, informing the treating physician of the appropriate therapy and informing the scientific community of the results of well-targeted, designed and performed clinical trials. With the advent of biological therapies able to manipulate the immune response more specifically, an understanding of the pathogenesis of these conditions is increasingly important. This review presents a broad overview of the pathogenesis, diagnosis and therapy of inflammatory neuropathies, concentrating on the most commonly encountered conditions.

show abstract

“…While clinical and electroneurographic patterns, together with their transient improvement after the immunomodulatory treatment,11 allow a diagnosis of anti-MAG PN, several concerns pertain the underlying CNS disease mimicking MS.…”

Section: Discussionmentioning

confidence: 99%

A case of anti-myelin-associated glycoprotein polyneuropathy and multiple sclerosis: one disease instead of two?

Sotgiu

Giua²,

Murrighile³

et al. 2009

Case Reports

View full text Add to dashboard Cite

A male patient diagnosed elsewhere as having multiple sclerosis (MS) was recently referred to our MS centre. Despite the presence of scattered T2-hyperintense MS-like lesions on MRI and cerebrospinal fluid (CSF) oligoclonal bands, his MS diagnosis was unpersuasive. Distal symmetric hypotonia, tendon areflexia and distal muscle weakness were present. A mostly demyelinating sensory polyneuropathy was disclosed at electroneurography. Serum IgM band, free monoclonal light chains and increased anti-myelin-associated glycoprotein IgM were detected. At 18 months later, and after three intravenous Ig treatments, a clinical electroneurographic improvement was evident along with the disappearance of some brain MRI lesions, reduction of serum anti-myelin-associated glycoprotein (MAG) IgM level and of the number of CSF oligoclonal bands. Although the cause/effect relation cannot be proven, we hypothesise that not only peripheral but also central demyelination may be related to the presence of anti-MAG antibodies with central nervous system (CNS) patterns on MRI resembling those seen in MS.

show abstract

Immunotherapy for IgM anti-Myelin-Associated Glycoprotein paraprotein-associated peripheral neuropathies

Abstract: Immunotherapy for IgM anti-myelin-associated glycoprotein paraprotein-associated peripheral neuropathies (Review)

Cited by 96 publications

References 51 publications

Fc receptor IIIA genotype is associated with rituximab response in antimyelin-associated glycoprotein neuropathy

Fc receptor IIIA genotype is associated with rituximab response in antimyelin-associated glycoprotein neuropathy

Diagnosis and treatment in inflammatory neuropathies

A case of anti-myelin-associated glycoprotein polyneuropathy and multiple sclerosis: one disease instead of two?

Contact Info

Product

Resources

About